Page 67 - rcv31n3.vp

Revista Uruguaya de Cardiología
Guía sobre doble antiagregación plaquetaria en pacientes con enfermedad coronaria
Volumen 31 | nº 3 | Diciembre 2016 Óscar Bazzino
dad de los puentes venosos (recomendación 9. Valgimigli M, Campo G, Monti M, Vranckx P,
clase IIb, nivel de evidencia B). Percoco G, Tumscitz C, et al. Short- versus
long-term duration of dual-antiplatelet therapy af-
tercoronary stenting: a randomized multicenter
trial. Circulation 2012;125(16):2015-26.
Bibliografía doi: 10.1161/CIRCULATIONAHA.111.071589
1. Levine GN, Bates ER, Bittl JA, Brindis RG,
Fihn SD, Fleisher LA, et.al. 2016 ACC/AHA Gui- 10. Collet J-P, Silvain J, Barthélémy O, Rangé G,
deline focused update on duration of dual antiplate- Cayla G, Van Belle E, et al. Dual-antiplatelet
let therapy in patients with coronary artery disease: treatment beyond 1 year after drug-eluting stentim-
a report of the American College of Cardiology/Ame- plantation (ARCTIC-Interruption): a randomised
rican Heart Association task force on clinical practice trial. Lancet. 2014;384(9954):1577-85. doi:
guidelines. J Am Coll Cardiol. 2016;68:1082-115 doi: 10.1016/S0140-6736(14)60612-7.
10.1016/j.jacc.2016.03.513.
11. Gilard M, Barragan P, Noryani AAL, Noor HA,
2. Mauri L, Kereiakes DJ, Yeh RW, Dris- Majwal T, Hovasse T, et al. 6- versus 24-month
coll-Shempp P, Cutlip DE, Steg PG, et al. Twel- dual antiplatelet therapy after implantation of
ve or 30 months of dual antiplatelet therapy after drug-elutingstents in patients nonresistant to aspi-
drug-eluting stents. N Engl J Med. 2014;371(23): rin: the randomized, multicenter ITALIC trial. J Am
2155-66. Coll Cardiol.2015;65(8):777-86.
doi: 10.1056/NEJMoa1409312. doi: 10.1016/j.jacc.2014.11.008.
3. Colombo A, Chieffo A, Frasheri A, Garbo R,
12. Lee CW, Ahn J-M, Park DW, Kang SJ, Lee SW,
Masotti-Centol M, et al. Second-generation
Kim YH, et al. Optimal duration of dual antiplatelet
drug-eluting stent implantation followed by 6- ver-
therapy after drug-eluting stentimplantation: a ran-
sus12-month dual antiplatelet therapy: the
domized, controlled trial. Circulation.
SECURITY randomized clinical trial. J Am Coll Car-
2014;129(3):304-12.
diol. 2014;64(20): 2086-97.
doi: 10.1161/CIRCULATIONAHA.113.003303.
4. Gwon H-C, Hahn J-Y, Park KW, Song YB, Chae
13. Helft G, Steg PG, Le Feuvre C, Georges JL, Ca-
IH, Lim DS, et al. Six-month versus 12-month dual
rrie D, Dreyfus X, et al. Stopping or continuing clo-
antiplatelet therapy after implantation ofdrug-elu-
pidogrel 12 months after drug-eluting stent place-
ting stents: the Efficacy of Xience/Promus Versus
ment: the OPTIDUAL randomized trial. Eur Heart
Cypher to Reduce Late Loss After Sten-
J. 2016;37(4):365-74. doi: 10.1093/eurheartj/ehv481.
ting(EXCELLENT) randomized, multicenter study.
Circulation 2012;125(3):505-13.
14. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Sto-
5. Kim B-K, Hong M-K, Shin D-H, Nam CM, Kim rey RF, Jensen EC, et al. Long-term use of ticagre-
JS, Ko YG, et al. A new strategy for discontinuation lor in patients with prior myocardial infarction. N
of dual antiplatelet therapy: the RESETTrial (REal Engl J Med. 2015;372(19):1791-800.
Safety and Efficacy of 3-month dual antiplatelet The- doi: 10.1056/NEJMoa1500857.
rapy following Endeavor zotarolimus-eluting sten-
timplantation). J Am Coll Cardiol. 2012;60(15): 15. Levine GN, Bates ER, Blankenship JC, Bailey
1340-8. doi: 10.1016/j.jacc.2012.06.043. SR, Bittl JA, Cercek B, et al. 2011 ACCF/
AHA/SCAI guideline for percutaneous coronaryin-
6. Feres F, Costa RA, Abizaid A, Leon MB, Ma- tervention: a report of the American College of Car-
rin-Neto JA, Botelho RV, et al. Three vs twelve diology Foundation/American Heart Association
months of dual antiplatelet therapy after zotaroli- Task Forceon Practice Guidelines and the Society for
mus-elutingstents: the OPTIMIZE randomized trial. Cardiovascular Angiography and Interventions. J
JAMA 2013;310(23):2510-22. Am Coll Cardiol.2011;58(24):e44-122.
7. Schulz-Schüpke S, Byrne RA, Ten Berg JM, doi: 10.1016/j.jacc.2011.08.007.
Neumann FJ, Han Y, Adriaenssens T, et al.
16. Hillis LD, Smith PK, Anderson JL, Bittl JA,
ISAR-SAFE: a randomized, double-blind, place-
Bridges CR, Byrne JG, et al. 2011 ACCF/AHA
bo-controlledtrial of 6 vs. 12 months of clopidogrel
guideline for coronary artery bypass graft surgery: a
therapy after drug-eluting stenting. Eur Heart J.
report of the American College of Cardiology Foun-
2015;36(20):1252-63.
dation/American Heart Association Task Force on
doi: 10.1093/eurheartj/ehu523.
Practice Guidelines. Developed in collaboration with
8. Park S-J, Park D-W, Kim Y-H, Kang SJ, Lee SW, the American Association for Thoracic Surgery, So-
Lee CW, et al. Duration of dual antiplatelet therapy ciety of Cardiovascular Anesthesiologists, and So-
after implantation of drug-eluting stents. N Engl J ciety of Thoracic Surgeons. J Am Coll Cardiol.
Med. 2010;362(15):1374-82. 2011;58(24):e123-210.
doi: 10.1056/NEJMoa1001266. doi: 10.1016/j.jacc.2011.08.009.
423